GI Diagnostics Expansion ALPCO has a strong focus on infectious and gastroenterological diseases with recent launches including Calprotectin Immunoturbidimetric Assay, signaling ongoing product expansion in GI diagnostics that presents cross-sell opportunities to labs seeking stool biomarker and inflammatory diagnostics.

Global Partnerships Strategic collaborations with Dynex Technologies and earlier partnerships with GeneProof and Gold Standard Diagnostics indicate a channel strategy that could be leveraged to create co-selling opportunities, bundled systems, or automated workflows for multiplex GI panels.

FDA Clearance Momentum FDA 510(k) clearance of Calprotectin Immunoturbidimetric Assay reinforces regulatory credibility and market access, creating a compelling case for hospitals and clinical laboratories to adopt ALPCO’s validated GI solutions.

Executive Leadership Recent CEO appointment and growth trajectory suggest a company in active market shaping and potential appetite for strategic partnerships, distribution deals, and regional expansion to accelerate penetration in mid-to-large labs.

Mid-market Footprint Revenue in the $25M-$50M range with 51-200 employees places ALPCO in the mid-market segment, presenting scalable procurement programs, volume-based discounts, and rep-driven sales motions that resonate with regional lab networks and diagnostic distributors.